For Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing colon cancer [79,80] and lung cancer [81,82,83] models, anti-HER2 antibody gene-recombinant HSV investigational drugs exert anti-tumor effects by inhibiting HER2 homo/heterodimerization, blocking pro-cancer signaling pathways [84], and recruiting immune effector cells (such as NK cells, macrophages) to produce ADCC effects. Here, ERBB2 is linked to lung carcinoma.